What are Indivior Pharmaceuticals, Inc. 's profit margins?

Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.

Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?

Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Indivior Pharmaceuticals, Inc. INDV Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$1.29B+10.2%	$1.24B+4.3%	$1.18B+1.5%	$1.17B+3.9%	$1.17B+6.1%
Total cost of revenue	$242M+2.1%	$246M+6.5%	$227M+0.2%	$210M+2.9%	$237M+40.7%
Gross profit	$1.05B+12.3%	$994M+3.8%	$954M+1.8%	$964M+4.2%	$934M-0.1%
Gross margin	81.3%+1.5pp	80.2%-0.4pp	80.8%+0.3pp	82.1%+0.2pp	79.8%-5.0pp
Research and development	$91M-9.9%	$97M-9.3%	$107M+1.9%	$96M-14.3%	$101M-12.2%
Selling, general and administrative	$626M+4.0%	$635M+3.8%	$621M+7.4%	$608M+5.3%	$602M+6.2%
Other operating expenses	——	——	——	——	$905M-7.2%
Total operating expenses	——	——	——	——	$905M-7.2%
Operating income	$333M+1,048%	$262M+589%	$227M+593%	$219M+284%	$29M+174%
Operating margin	25.8%+23.3pp	21.1%+17.9pp	19.2%+23.2pp	18.7%+29.2pp	2.5%+6.0pp
Interest expense	$40M-11.1%	$45M+7.1%	$52M+37.7%	$51M+43.7%	$45M+27.7%
Interest income	$21M+5.0%	$22M-4.3%	$21M-27.0%	$20M-42.0%	$20M-49.0%
Gain (loss) on extinguishment of debt	——	——	——	——	——
Income before income taxes	$295M+4,817%	$239M+1,095%	$196M+461%	$189M+257%	$6M+117%
Income tax expense	——	——	$67M+866%	$80M+472%	$13M+500%
Net income	$251M+3,686%	$209M+2,886%	$128M+381%	$108M+209%	-$7M+79.1%
Net margin	19.4%+20.0pp	16.9%+16.3pp	10.8%+14.7pp	9.2%+18.0pp	-0.6%+2.4pp
Diluted earnings per share	$1.95+9,850%	$1.64+3,180%	$1.01+397%	$0.84+215%	-$0.02+91.7%
Basic earnings per share	$2.01+10,150%	$1.68+3,260%	$1.03+403%	$0.85+216%	-$0.02+91.7%
Weighted-average shares, diluted	512M-2.7%	508M-5.6%	513M-5.4%	517M—	526M—
Weighted-average shares, basic	499M-4.6%	499M-6.7%	506M-6.3%	513M—	523M—
Research and development expense	$91M-9.9%	$97M-9.3%	$107M+1.9%	$96M-14.3%	$101M-12.2%
Revenue From Contract With Customer Excluding Assessed Tax	$1.29B+10.2%	$1.24B+4.3%	$1.18B+1.5%	$1.17B+3.9%	$1.17B+6.1%
EBIT	$333M+1,048%	$262M+589%	$227M+593%	$219M+284%	$29M+174%
EBITDA	$342M+695%	$272M+404%	$240M+868%	$233M+323%	$43M+289%
EBITDA	$342M+695%	$272M+404%	$240M+868%	$233M+323%	$43M+289%
EBITDA margin	26.5%+22.8pp	21.9%+17.4pp	20.3%+23.0pp	19.8%+29.1pp	3.7%+5.7pp
EBIT	$333M+1,048%	$262M+589%	$227M+593%	$219M+284%	$29M+174%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Indivior Pharmaceuticals, Inc. 's profit margins?: Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.
Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?: Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.